Wiggin and Dana represented Affibody AB on the deal. Affibody AB signed a partnership agreement with ACELYRIN, INC. to develop and commercialize izokibep, a bispecific molecule targeting interleukin-17A…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
